HopeStage
Back to all studies
TerminatedNCT00439634

Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia

Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.

Medication studyAges 18–65United States + Canada
The study in practice

Understand this study

What is this study about?

Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.

Who could participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Listed locations
Bridgewater and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateFebruary 2007
Recruitment status
Terminated
Enrollment listed in the registry
873
Sponsor
Sanofi
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Canada
Age range
From 18 Years to 65 Years
Official registry ID
NCT00439634
Official title
Show the full official title

A 24-Week, Multicenter, Double-Blind, Randomized, Parallel-Group, Dose Ranging Study of the Efficacy and Safety of 3 Oral Doses of AVE1625 and Placebo on Top of Either Olanzapine, Risperidone/Paliperidone, Quetiapine or Aripiprazole in the Treatment of Cognitive Impairment in Schizophrenia.

Recruitment & locations

Terminated

Bridgewater, United States · Laval, Canada

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What is this study about?

Researchers are comparing AVE1625 and placebo to find out how the approaches affect memory, attention and other thinking skills in people with schizophrenia.

Who is behind this study?

The study sponsor is Sanofi.

Does this study involve medication?

Yes. The study involves medication, including AVE1625 and placebo.

Who can participate?

This study is for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies